Side-by-side · Research reference

MT-1vsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED9/51 cited

BPhase 3HUMAN-REVIEWED8/39 cited

MT-1

α-MSH Analogue · FDA-Approved

16 mgImplant dose

13 AAPeptide lengthChawathe 2026

2019FDA approval

SQ Implant · 60-Day Release

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

MT-1

Thymosin α-1

Primary target

Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production

—

Origin

Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

MT-1

Thymosin α-1

Standard dose

16 mg subcutaneous implant

FDA-approved formulation (Scenesse).

—

Frequency

Every 60 days

Sustained release implant — no daily administration required.

2× weekly (Mon/Thu typical)

Evidence basis

Phase 3 RCT / FDA-approved orphan drug

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Indication

Erythropoietic protoporphyria (EPP)

Narrow FDA approval — not licensed for cosmetic tanning.

—

Duration

Seasonal use (spring–autumn typical)

Aligned with peak UV exposure months.

6–12 months for chronic indications

Route

Subcutaneous implant — upper arm or abdomen

—

Stability

Norleucine/D-Phe substitutions enhance peptidase resistance

Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).

—

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

Lower / starter dose

—

0.8 mg per injection

Reconstitution

—

Sterile water for injection per vial label

Timing

—

No specific time

Half-life

—

~2 hours plasma; tissue effect days

04Side Effects & Safety

Parameter

MT-1

Thymosin α-1

Nausea

Common (>10%) — mild, transient

—

Implant site reaction

Erythema, bruising, tenderness at insertion site

—

Hyperpigmentation

Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010 Habbema 2017

Expected melanogenic response — complicates pigmented lesion surveillance.

—

Melanocytic changes

Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017

Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.

—

Headache

Occasional (MC1R-independent melanocortin effects)

—

Photosensitivity (paradoxical)

Rare phototoxic reactions despite melanin increase

—

Contamination risk (unregulated)

Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010 Habbema 2017

Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.

—

Injection site reaction

—

Erythema, mild discomfort

GI symptoms

—

Rare nausea

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Cancer risk

—

No signal — used as adjuvant in oncology

Pregnancy / OB

—

Avoid

Absolute Contraindications

MT-1

·Hypersensitivity to afamelanotide or excipients
·Hepatic impairment (no safety data)
·Renal impairment (no safety data)

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

MT-1

·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
·Pregnancy/lactation (insufficient data)
·Photosensitive dermatoses (other than EPP)

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

MT-1

Thymosin α-1

1. Implant insertion

Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Site care

Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Release kinetics

Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.

2× weekly, e.g. Monday + Thursday.

4. Repeat dosing

New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Monitoring

Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.

27–31G, 4–8 mm insulin syringe.